Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Fineline Cube Jul 13, 2026
Company Deals

InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments

Fineline Cube Jul 13, 2026
Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Fineline Cube Jul 13, 2026
Company Drug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

Fineline Cube Jul 13, 2026
Company Deals

Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy

Fineline Cube Mar 10, 2025

India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of...

Company Drug

Pfizer’s Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma

Fineline Cube Mar 10, 2025

US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration...

Company

MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024

Fineline Cube Mar 10, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....

Company Medical Device

SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China

Fineline Cube Mar 10, 2025

Shenzhen-based SonoScape Medical Corp. announced receiving marketing approval in China for its S-Fetus prenatal ultrasound...

Company Drug

TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis

Fineline Cube Mar 10, 2025

Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...

Company Deals

Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments

Fineline Cube Mar 10, 2025

On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance...

Company Drug

AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial

Fineline Cube Mar 10, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...

Company Deals

NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter

Fineline Cube Mar 9, 2025

NewCo is a new transaction model developed by Chinese innovative drug companies in response to...

Company

Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development

Fineline Cube Mar 9, 2025

Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s...

Company Deals

Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights

Fineline Cube Mar 7, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s...

Company Drug

Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment

Fineline Cube Mar 7, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...

Company Drug

Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16

Fineline Cube Mar 7, 2025

China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical...

Company Drug

Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease

Fineline Cube Mar 7, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...

Company Drug

Johnson & Johnson Terminate Phase III VENTURA Program for Aticaprant in adjunctive treatment of MDD

Fineline Cube Mar 7, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced the termination of the Phase III...

Company Drug

Gan & Lee Pharmaceuticals Joins Brazil’s PDP for Localized Insulin Production

Fineline Cube Mar 7, 2025

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million...

Company Drug

Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials

Fineline Cube Mar 7, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...

Company Deals

4C Medical Lands $175M Series D to Advance AltaValve TMVR System

Fineline Cube Mar 7, 2025

US-based 4C Medical Technologies, Inc., a medical device company controlled by China-based MicroPort CardioFlow Medtech...

Company

Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences

Fineline Cube Mar 7, 2025

German major Merck KGaA (ETR: MRK) this week released its 2024 annual report, highlighting a...

Company Deals

Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform

Fineline Cube Mar 7, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with...

Company Drug

Johnson & Johnson Officially Launches Spravato in China for Depression Treatment

Fineline Cube Mar 7, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in...

Posts pagination

1 … 227 228 229 … 693

Recent updates

  • Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer
  • Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies
  • Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma
  • Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan
  • Roche Secures CE Mark for Elecsys IGRA TB Test, Delivering Automated Solution for Tuberculosis Infection Detection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Company Drug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

Company Drug

Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.